Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

The accepted abstract is listed below and now available at jacionline.org .

Presentation Title : PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients With Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy Session Title : Late Breaking Oral Abstract Session Session Date & Time : Saturday, March 14, 2020 from 2:00 – 3:15 p.m. ET Presenter : Cem Akin, M.D., Ph.D. Abstract ID : 12615

Conference Call Information Blueprint Medicines will host a live webcast on Monday, March 16, 2020 beginning at 8:00 a.m. ET to discuss the updated data from the PIONEER trial. To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international), and refer to conference ID 1590639. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com . The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

SOURCE Blueprint Medicines Corporation